These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 19692326)

  • 1. The high-dose aldesleukin (IL-2) "select" trial: a trial designed to prospectively validate predictive models of response to high-dose IL-2 treatment in patients with metastatic renal cell carcinoma.
    Clement JM; McDermott DF
    Clin Genitourin Cancer; 2009 Aug; 7(2):E7-9. PubMed ID: 19692326
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interleukin-2 therapy of metastatic renal cell carcinoma--predictors of response.
    McDermott DF; Atkins MB
    Semin Oncol; 2006 Oct; 33(5):583-7. PubMed ID: 17045087
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of metastatic renal cell carcinoma.
    Reeves DJ; Liu CY
    Cancer Chemother Pharmacol; 2009 Jun; 64(1):11-25. PubMed ID: 19343348
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term follow-up of patients with metastatic renal cell carcinoma treated with intravenous recombinant interleukin-2 in Europe.
    Negrier S; Maral J; Drevon M; Vinke J; Escudier B; Philip T
    Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S93-8. PubMed ID: 10685667
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interleukin-2 therapy of metastatic renal cell carcinoma: update of phase III trials.
    McDermott DF; Regan MM; Atkins MB
    Clin Genitourin Cancer; 2006 Sep; 5(2):114-9. PubMed ID: 17026799
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The high-dose aldesleukin "select" trial: a trial to prospectively validate predictive models of response to treatment in patients with metastatic renal cell carcinoma.
    McDermott DF; Cheng SC; Signoretti S; Margolin KA; Clark JI; Sosman JA; Dutcher JP; Logan TF; Curti BD; Ernstoff MS; Appleman L; Wong MK; Khushalani NI; Oleksowicz L; Vaishampayan UN; Mier JW; Panka DJ; Bhatt RS; Bailey AS; Leibovich BC; Kwon ED; Kabbinavar FF; Belldegrun AS; Figlin RA; Pantuck AJ; Regan MM; Atkins MB
    Clin Cancer Res; 2015 Feb; 21(3):561-8. PubMed ID: 25424850
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aldesleukin for metastatic renal cell carcinoma?
    Drug Ther Bull; 1993 Apr; 31(8):29-30. PubMed ID: 8348884
    [No Abstract]   [Full Text] [Related]  

  • 8. Aldesleukin in advanced renal cell carcinoma.
    Schmidinger M; Hejna M; Zielinski CC
    Expert Rev Anticancer Ther; 2004 Dec; 4(6):957-80. PubMed ID: 15606326
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical study on recombinant human interleukin-2 (Proleukin) in the treatment of metastatic renal cell carcinoma].
    Sheng XN; Li JL; Guo J; Zhao XH; Zhu J; Chu DT
    Zhonghua Zhong Liu Za Zhi; 2008 Feb; 30(2):129-33. PubMed ID: 18646697
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotherapy of metastatic renal cell carcinoma.
    McDermott DF; Atkins MB
    Cancer J; 2008; 14(5):320-4. PubMed ID: 18836337
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Temsirolimus in renal cell carcinoma.
    Otto T; Eimer C; Gerullis H
    Transplant Proc; 2008 Dec; 40(10 Suppl):S36-9. PubMed ID: 19100905
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II trial of sequential radiation and interleukin 2 in the treatment of patients with metastatic renal cell carcinoma.
    Redman BG; Hillman GG; Flaherty L; Forman J; Dezso B; Haas GP
    Clin Cancer Res; 1998 Feb; 4(2):283-6. PubMed ID: 9516912
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and safety profile of high-dose interleukin-2 treatment in elderly patients with metastatic melanoma and renal cell carcinoma.
    Clark JM; Kelley B; Titze J; Fung H; Maciejewski J; Nathan S; Rich E; Basu S; Kaufman HL
    Oncology; 2013; 84(2):123-6. PubMed ID: 23235386
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytokine therapy: a standard of care for metastatic renal cell carcinoma?
    Hutson TE; Quinn DI
    Clin Genitourin Cancer; 2005 Dec; 4(3):181-6. PubMed ID: 16425986
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Update on the role of interleukin 2 and other cytokines in the treatment of patients with stage IV renal carcinoma.
    Atkins MB; Regan M; McDermott D
    Clin Cancer Res; 2004 Sep; 10(18 Pt 2):6342S-6S. PubMed ID: 15448028
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improving the therapeutic index of IL-2.
    McDermott DF
    Clin Adv Hematol Oncol; 2010 Dec; 8(12):862-4. PubMed ID: 21326162
    [No Abstract]   [Full Text] [Related]  

  • 17. High-dose interleukin-2 can produce a high rate of response and durable remissions in appropriately selected patients with metastatic renal cancer.
    Shablak A; Sikand K; Shanks JH; Thistlethwaite F; Spencer-Shaw A; Hawkins RE
    J Immunother; 2011 Jan; 34(1):107-12. PubMed ID: 21150719
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Precision medicine for metastatic renal cell carcinoma.
    Sonpavde G; Choueiri TK
    Urol Oncol; 2014 Jan; 32(1):5-15. PubMed ID: 24239472
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunochemotherapy with interleukin-2, interferon-alpha and 5-fluorouracil for progressive metastatic renal cell carcinoma: a multicenter phase II study. Dutch Immunotherapy Working Party.
    van Herpen CM; Jansen RL; Kruit WH; Hoekman K; Groenewegen G; Osanto S; De Mulder PH
    Br J Cancer; 2000 Feb; 82(4):772-6. PubMed ID: 10732744
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Should high-dose interleukin-2 still be the preferred treatment for patients with metastatic renal cell cancer?
    Dillman RO; Barth NM; VanderMolen LA; Fong WH; Mahdavi KK; McClure SE
    Cancer Biother Radiopharm; 2011 Jun; 26(3):273-7. PubMed ID: 21711094
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.